LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling

BACKGROUND: The genesis of SMAC mimetic drugs is founded on the observation that many cancers amplify IAP proteins to facilitate their survival, and therefore removal of these pathways would re-sensitize the cells towards apoptosis. It has become increasingly clear that SMAC mimetics also interface...

Descripción completa

Detalles Bibliográficos
Autores principales: Afsahi, Arya, Silvestri, Christopher M., Moore, Allyson E., Graham, Carly F., Bacchiochi, Kaylyn, St-Jean, Martine, Baker, Christopher L., Korneluk, Robert G., Beug, Shawn T., LaCasse, Eric C., Bramson, Jonathan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150108/
https://www.ncbi.nlm.nih.gov/pubmed/37138866
http://dx.doi.org/10.3389/fimmu.2023.1179827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150108/
https://www.ncbi.nlm.nih.gov/pubmed/37138866
http://dx.doi.org/10.3389/fimmu.2023.1179827

Ejemplares similares